Daewon Pharmaceutical Co., Ltd.
Clinical trials sponsored by Daewon Pharmaceutical Co., Ltd., explained in plain language.
A South Korean pharmaceutical company manufacturing and marketing generic and branded drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
First human tests begin for new drug DW4421
Knowledge-focused Not yet recruitingThis early-stage trial evaluates the safety of multiple doses of an investigational drug called DW4421 in healthy adults aged 19 to 50. Researchers will measure how the drug moves through the body and how it is processed. The study aims to gather essential safety and dosing infor…
Phase: PHASE1 • Sponsor: Daewon Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
New drug DW4421 put through interaction test with common antibiotics
Knowledge-focused Not yet recruitingThis early-stage trial will test how a new drug called DW4421 interacts with two common antibiotics (amoxicillin and clarithromycin) in 36 healthy adults aged 19 to 50. The study measures safety and how the drug levels change when taken together. It does not aim to treat any dise…
Phase: PHASE1 • Sponsor: Daewon Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Healthy volunteers needed to test two new drug formulations in Early-Stage trial
Knowledge-focused Not yet recruitingThis early-stage study tests two experimental drugs (DW4421-T1 and DW4421S-T1) in 38 healthy adults aged 19 to 50. The goal is to check how safe they are and how the body processes them. Participants will receive a single dose of each drug in a random order and be monitored close…
Phase: PHASE1 • Sponsor: Daewon Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
New drug DW5524 tested in healthy people for first time
Knowledge-focused Not yet recruitingThis early-phase trial will test the safety and how the body handles a single dose of DW5524 in 48 healthy adults. Participants will be randomly assigned to receive either DW5524 or a related version, DW5524-A. The study aims to understand the drug's effects and how it moves thro…
Phase: PHASE1 • Sponsor: Daewon Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC